Not applicableUnknownNCT05559528What this trial is testingBRaziLian outcomE for metAStatic breasT CancerWho this might be right forMetastatic Breast CancerBreast Cancer Stage IV Hospital do Coracao 300
Large-scale testing (Phase 3)Looking for participantsNCT05901428What this trial is testingTCb vs EC-T in High Risk ER+/HER2- Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast Cancer Fudan University 1,736
Testing effectiveness (Phase 2)Active Not RecruitingNCT05596409What this trial is testingELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyWho this might be right forMetastatic Breast Cancer Stemline Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Study completedNCT01105312What this trial is testingPanobinostat and Letrozole in Treating Patients With Metastatic Breast CancerWho this might be right forBreast Cancer Alliance for Clinical Trials in Oncology 28
Early research (Phase 1)Study completedNCT02672475What this trial is testingGalunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerWho this might be right forEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more Vanderbilt-Ingram Cancer Center 29
Early research (Phase 1)Ended earlyNCT01071564What this trial is testingRO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By SurgeryWho this might be right forEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+5 more National Cancer Institute (NCI) 13
Large-scale testing (Phase 3)Study completedNCT04629846What this trial is testingStudy in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.Who this might be right forBreast Cancer Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Looking for participantsNCT06923527What this trial is testingCirculating Tumor DNAWho this might be right forER+ Breast Cancer Yale University 50
Testing effectiveness (Phase 2)Study completedNCT02971761What this trial is testingPembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerWho this might be right forAndrogen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more City of Hope Medical Center 18
Testing effectiveness (Phase 2)Ended earlyNCT00661531What this trial is testingEstrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine TherapyWho this might be right forBreast CancerCancer of the BreastNeoplasms, Breast Georgetown University 11
Testing effectiveness (Phase 2)Looking for participantsNCT04606446What this trial is testingStudy of PF-07248144 in Advanced or Metastatic Solid TumorsWho this might be right forLocally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer Pfizer 320
Early research (Phase 1)Ended earlyNCT01149356What this trial is testingRO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerWho this might be right forEstrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more National Cancer Institute (NCI) 15
Early research (Phase 1)Looking for participantsNCT07540572What this trial is testingInvestigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsWho this might be right forER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more IDEAYA Biosciences 160
Testing effectiveness (Phase 2)WithdrawnNCT03872505What this trial is testingPre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerWho this might be right forBreast CancerTriple Negative Breast Cancer Cedars-Sinai Medical Center
Very early researchStudy completedNCT03599453What this trial is testingChemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerWho this might be right forTriple -Negative Breast CancerEstrogen Receptor NegativeHER2/Neu Negative+2 more Roswell Park Cancer Institute 8
Early research (Phase 1)UnknownNCT05673694What this trial is testingTo Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.Who this might be right forBreast Cancer Changchun GeneScience Pharmaceutical Co., Ltd. 70
Not applicableLooking for participantsNCT06417801What this trial is testingMinimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.Who this might be right forMetastatic Breast Cancer AstraZeneca 170
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271What this trial is testingSafety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone TherapyWho this might be right forPrimary Non-metastatic Breast CancerWho Remain Disease-free UNICANCER 1,278
Large-scale testing (Phase 3)Study completedNCT00253422What this trial is testingStudy of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsWho this might be right forBreast Cancer Institute of Cancer Research, United Kingdom 698
Early research (Phase 1)Study completedNCT04176757What this trial is testingZN-c5 in Participants With Breast CancerWho this might be right forBreast Cancer Zeno Alpha Inc. 35